Page 402 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

380 PART IV Specific Malignancies in the Small Animal Patient

145. Wergin MC, Roos M, Inteeworn N, et al.: The influence of frac- 166. Kitchell BE, Brown DM, Luck EE, et al.: Intralesional implant for
tionated radiation therapy on plasma vascular endothelial growth treatment of primary oral malignant melanoma in dogs, J Am Vet
factor (VEGF) concentration in dogs with spontaneous tumors and Med Assoc 204:229–236, 1994.
VetBooks.ir 146. Wergin MC, Kaser-Hotz B: Plasma vascular endothelial growth 167. Theon AP, Madewell BR, Moore AS, et al.: Localized thermo-
its impact on outcome, Radiother Oncol 79:239–244, 2006.
cisplatin therapy: a pilot study in spontaneous canine and feline
factor (VEGF) measured in seventy dogs with spontaneously
tumours, Int J Hyperthermia 7:881–892, 1991.
occurring tumours, Vivo 18:15–19, 2004. 168. Spugnini EP, Dragonetti E, Vincenzi B, et al.: Pulse-mediated
147. Page RL, Thrall DE, Dewhirst MW, et al.: Phase I study of mel- chemotherapy enhances local control and survival in a spontane-
phalan alone and melphalan plus whole body hyperthermia in dogs ous canine model of primary mucosal melanoma, Melanoma Res
with malignant melanoma, Int J Hyperthermia 7:559–566, 1991. 16:23–27, 2006.
148. Ogilvie GK, Reynolds HA, Richardson RC, et al.: Phase II evalu- 169. Alexander AN, Huelsmeyer MK, Mitzey A, et al.: Development
ation of doxorubicin for treatment of various canine neoplasms, of an allogeneic whole-cell tumor vaccine expressing xenogeneic
J Am Vet Med Assoc 195:1580–1583, 1989. gp100 and its implementation in a phase II clinical trial in canine
149. Aigner K, Hild P, Breithaupt H, et al.: Isolated extremity perfu- patients with malignant melanoma, Cancer Immunol Immunother
sion with DTIC. An experimental and clinical study, Anticancer Res 55:433–442, 2006.
3:87–93, 1983. 170. Hogge GS, Burkholder JK, Culp J, et al.: Preclinical development
150. Wouda RM, Miller ME, Chon E, et al.: Clinical effects of vinorel- of human granulocyte-macrophage colony-stimulating factor-
bine administration in the management of various malignant transfected melanoma cell vaccine using established canine cell
tumor types in dogs: 58 cases (1997-2012), J Am Vet Med Assoc lines and normal dogs, Cancer Gene Ther 6:26–36, 1999.
246:1230–1237, 2015. 171. Macewen EG, Kurzman ID, Vail DM, et al.: Adjuvant therapy for
151. Boria PA, Murry DJ, Bennett PF, et al.: Evaluation of cisplatin melanoma in dogs: results of randomized clinical trials using sur-
combined with piroxicam for the treatment of oral malignant mela- gery, liposome-encapsulated muramyl tripeptide, and granulocyte
noma and oral squamous cell carcinoma in dogs, J Am Vet Med macrophage colony-stimulating factor, Clin Cancer Res 5: 4249–
Assoc 224:388–394, 2004. 4258.
152. Rassnick KM, Ruslander DM, Cotter SM, et al.: Use of carboplatin 172. Bianco SR, Sun J, Fosmire SP, et al.: Enhancing antimelanoma
for treatment of dogs with malignant melanoma: 27 cases (1989- immune responses through apoptosis, Cancer Gene Ther 10:726–
2000), J Am Vet Med Assoc 218:1444–1448, 2001. 736, 2003.
153. Brockley LK, Cooper MA, Bennett PF: Malignant melanoma in 173. Dow SW, Elmslie RE, Willson AP, et al.: In vivo tumor transfec-
63 dogs (2001-2011): the effect of carboplatin chemotherapy on tion with superantigen plus cytokine genes induces tumor regres-
survival, NZ Vet J 61:25–31, 2013. sion and prolongs survival in dogs with malignant melanoma,
154. Enjoji S, Yabe R, Fujiwara N, et al.: The therapeutic effects of SET/ J Clin Invest 101:2406–2414, 1998.
I2PP2A inhibitors on canine melanoma, J Vet Med Sci 77:1451– 174. Gyorffy S, Rodriguez-Lecompte JC, Woods JP, et al.: Bone marrow-
1456, 2015. derived dendritic cell vaccination of dogs with naturally occurring
155. Breit MN, Kisseberth WC, Bear MD, et al.: Biologic activity of melanoma by using human gp100 antigen, J Vet Intern Med 19:56–
the novel orally bioavailable selective inhibitor of nuclear export 63, 2005.
(SINE) KPT-335 against canine melanoma cell lines, BMC Vet Res 175. Helfand SC, Soergel SA, Modiano JF, et al.: Induction of lymphokine-
10(160), 2014. activated killer (LAK) activity in canine lymphocytes with low dose
156. London CA, Bernabe LF, Barnard S, et al.: Preclinical evaluation human recombinant interleukin-2 in vitro, Cancer Biother 9:237–244,
of the novel, orally bioavailable selective inhibitor of nuclear export 1994.
(SINE) KPT-335 in spontaneous canine cancer: results of a phase I 176. Mayayo SL, Prestigio S, Maniscalco L, et al.: Chondroitin sulfate
study, PLoS One 9:e87585, 2014. proteoglycan-4: a biomarker and a potential immunotherapeutic
157. Ito K, Kobayashi M, Kuroki S, et al.: The proteasome inhibitor target for canine malignant melanoma, Vet J 190:e26–e30, 2011.
bortezomib inhibits the growth of canine malignant melanoma 177. Moriyama M, Kano R, Maruyama H, et al.: Small interfering RNA
cells in vitro and in vivo, Vet J 198:577–582, 2013. (siRNA) against the survivin gene increases apoptosis in a canine
158. Yokoe I, Azuma K, Hata K, et al.: Clinical systemic lupeol admin- melanoma cell line, J Vet Med Sci 72:1643–1646, 2010.
istration for canine oral malignant melanoma, Mol Clin Oncol 178. Watanabe Y, Kano R, Maruyama H, et al.: Small interfering RNA
3:89–92, 2015. (siRNA) against the Bcl-2 gene increases apoptosis in a canine mel-
159. O’Day S, Boasberg P: Management of metastatic melanoma 2005, anoma cell line, J Vet Med Sci 72:383–386, 2010.
Surg Oncol Clin North Am 15:419–437, 2006. 179. Thamm DH, Kurzman ID, Clark MA, et al.: Preclinical investiga-
160. Martinez CD, Penafiel-Verdu C, Vilafranca M, et al.: Cyclo- tion of PEGylated tumor necrosis factor alpha in dogs with sponta-
oxygenase-2 expression is related with localization, proliferation, neous tumors: phase I evaluation, Clin Cancer Res 16:1498–1508,
and overall survival in canine melanocytic neoplasms, Vet Pathol 2010.
48:1204–1211, 2011. 180. Finocchiaro LM, Fiszman GL, Karara AL, et al.: Suicide gene and
161. Pires I, Garcia A, Prada J, et al.: COX-1 and COX-2 expression in cytokines combined nonviral gene therapy for spontaneous canine
canine cutaneous, oral and ocular melanocytic tumours, J Comp melanoma, Cancer Gene Ther 15:165–172, 2008.
Pathol 143:142–149, 2010. 181. Finocchiaro LM, Glikin GC: Cytokine-enhanced vaccine and sui-
162. Paglia D, Dubielzig RR, Kado-Fong HK, et al.: Expression of cide gene therapy as surgery adjuvant treatments for spontaneous
cyclooxygenase-2 in canine uveal melanocytic neoplasms, Am J Vet canine melanoma, Gene Ther 15:267–276, 2008.
Res 70:1284–1290, 2009. 182. Gil-Cardeza ML, Villaverde MS, Fiszman GL, et al.: Suicide gene
163. Yoshitake R, Saeki K, Watanabe M, et al.: Molecular investigation therapy on spontaneous canine melanoma: correlations between
of the direct anti-tumour effects of nonsteroidal anti-inflammatory in vivo tumors and their derived multicell spheroids in vitro, Gene
drugs in a panel of canine cancer cell lines, Vet J 221:38–47, 2017. Ther 17:26–36, 2010.
164. Gregorio H, Raposo TP, Queiroga FL, et al.: Investigating asso- 183. von EH, Sadeghi A, Carlsson B, et al.: Efficient adenovector CD40
ciations of cyclooxygenase-2 expression with angiogenesis, pro- ligand immunotherapy of canine malignant melanoma, J Immuno-
liferation, macrophage and T-lymphocyte infiltration in canine ther 31:377–384, 2008.
melanocytic tumours, Melanoma Res 26:338–347, 2016. 184. Piras LA, Riccardo F, Iussich S, et al.: Prolongation of survival
165. Seo KW, Coh YR, Rebhun RB, et al.: Antitumor effects of cele- of dogs with oral malignant melanoma treated by en bloc surgi-
coxib in COX-2 expressing and non-expressing canine melanoma cal resection and adjuvant CSPG4-antigen electrovaccination, Vet
cell lines, Res Vet Sci 96:482–486, 2014. Comp Oncol 15:996–1013, 2017.